UTv Videos

“We've made great strides with bladder preservation on many fronts,” says Sophia C. Kamran, MD.

Shilpa Gupta, MD, discusses long-term outcomes of the EV-103 trial, which explored the first-line combination of enfortumab vedotin and pembrolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

“Our ultimate goal is to come up with strategies that really enhance the life expectancy and the treatment options for our patients with urothelial cancer,” says Arlene O. Siefker-Radtke, MD.

“We will never be satisfied with doing ‘just good enough’ for our patients,” says Colin P. West, MD, PhD.

"In this trial, and in all the major IO/TKI trials, the checkpoint inhibitor stopped at 2 years. In this trial it was about 25% of patients who made it to that time point," says Brian I. Rini, MD.

"Unfortunately, I don't think that the triplet of cabo/nivo/ipi is ready as the current dosing for use in RCC with variant histology," says Bradley McGregor, MD.

"All the patients said that they were pleased with the acupuncture that they received, and about 75% said that they would refer other people going through BCG to acupuncture," says Sarah P. Psutka, MD, MS.

"There was a striking decreased survival for patients who had sarcomatoid histology compared to the ones who had the classic variant urothelial histology," says Rohan Garje, MD.

David Olmos, MBBS, MSc, PhD, discusses research presented at the ASCO 2023 Annual Meeting assessing outcomes with first-line novel hormonal therapy or taxane therapy in metastatic castration-resistant prostate cancer based on patients' BRCA/HRR status.

"The overall survival, Kaplan Meier curves, are maintained with a hazard ratio of 0.79 for the intent-to-treat patient population of lenvatinib/pembrolizumab versus sunitinib," said Thomas E. Hutson, DO, PharmD, FACP.

"Our research focused on the outcomes at 6 months, [and we] were looking at disease recurrence and hernia occurrence," says Jennifer Nguyen.

"About 80% of the patients who underwent treatment showed a very strong reduction in tryptase levels," says Praveen Thumbikat, DVM, PhD.

“There are a lot of social determinants of health as it relates to urge urinary incontinence,” says Joseph Kim, MD.

"Here, we've lowered the age to initiate screening to 45 to 50 years," says Badrinath R. Konety, MD, MBA.

"Even though most urologists who do retroperitoneal surgery do it for posterior tumors, you actually can do it equally well with as equally good success for an anterior tumor," says Michael D. Stifelman, MD.

"Our main finding was that participants who experienced food insecurity in the past year were at 55% increased odds of reporting at least 1 episode of urge urinary incontinence in the past month, compared with those who have not experienced food insecurity," says Joseph Kim, MD.

"I think there's a lot of interest now on intraoperative navigation," says Jihad Kaouk, MD.

“The take-home message is that as a practicing urologist, you should be treating genitourinary syndrome of menopause and giving any woman over 45 vaginal hormones, whether in the form of vaginal estrogen or vaginal DHEA,” says Rachel S. Rubin, MD.

“We really wanted to give the general urologist the tools to go back to the clinic the next day and say, "I know how to prescribe this. I know where to prescribe it. I know the cheapest options. I know the best deals around and I know how to talk to patients about the risks and the benefits,” says Rachel S. Rubin, MD.

The data were presented at the 2023 American Urological Association Annual Meeting in Chicago, Illinois.

“The purpose of health care is to provide health care. And...the more we can focus on that, the more we can leverage the hope that I do think that we have,” says Colin P. West, MD, PhD.

"One of the factors that goes into why transperineal [biopsies] aren't performed more readily in the US is lack of exposure," says Jim C. Hu, MD, MPH.

“It's a challenge to get funding for these types of studies, and also to have the infrastructure to carry out a lot of these big studies. But there's no question that we need more data,” says Rachel S. Rubin, MD.

“Approaching wellbeing is a shared responsibility,” says Colin P. West, MD, PhD.

"What we found was a very different frequency of alterations in important genes," says Camilo Arenas-Gallo, MD.

“Those who were on this vaginal DHEA had a huge decrease in the prevalence of urinary tract infections in the 1 year after getting the prescription,” says Rachel S. Rubin, MD.

"We have to be intentional in order to design our trials so that we have a better participation of those groups," says Larissa V. Rodriguez, MD.

"We have become more advanced over time. We understand that men's health is more than just testosterone. Men's health is more than just erectile function and prostate disease," says Michael D. Lutz, MD.

“We need to experience fairness and respect, and we need to see that our individual values align with the values of our organizations, and of our health care system as a whole,” says Colin P. West, MD, PhD.

"What we found is that AI+ score using continuous variables had the highest predictive ability of all oncologic outcomes that were measured," says Nour Abdallah, MD.